Please use this identifier to cite or link to this item:
Title: A narrative review on the effectiveness of tocilizumab in reducing the mortality risk in covid-19 patients
Authors: Nur Haifa Amani Zulkiply
Vignesh, Ramachandran
Muthukumarasamy, Ravindran
Keywords: COVID-19
Cytokine storm
Interleukin-6 inhibitors
Issue Date: Jul-2021
Publisher: Universiti Putra Malaysia Press
Citation: Nur Haifa Amani Zulkiply, Vignesh, R., & Muthukumarasamy, R. (2021). A Narrative Review on the Effectiveness of Tocilizumab in Reducing the Mortality Risk in COVID-19 Patients. Malaysian Journal of Medicine and Health Sciences, 17(3), 2636–9346.
Abstract: The novel coronavirus disease 2019 (COVID-19) has reached its pandemic scale within a short period of its first case reported in Wuhan, China in December 2019, leading to a great economic crisis all over the world. As of today, there is no clinically approved antiviral drug available for the treatment of COVID-19. Tocilizumab, a humanized monoclonal antibody against the interleukin-6 (IL-6) receptor, clinically approved for the treatment of rheumatoid arthritis, is one such drug used to manage the COVID-19 symptoms. The current study reviews the effectiveness of Tocilizumab as a treatment option for COVID-19. Research findings on Tocilizumab are effective in COVID-19 patients with the risk of cytokine storm and further complications. Nevertheless, this review also recommends further investigation on the effectiveness of this drug with a large group of patients for more accuracy in results with COVID 19 patients
ISSN: 16758544
Appears in Collections:Journal Articles

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.